Chemomab Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts that cover Chemomab Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $26.5, which forecasts a 789.26% increase in the stock price over the next year. The lowest target is $25 and the highest is $28.

Price Target: $26.5 (+789.26%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$26.5	$28	$28
Change	+738.93%	+789.26%	+839.60%	+839.60%

* Price targets were last updated on Aug 27, 2025.

Analyst Ratings

The average analyst rating for Chemomab Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	May '25	Jun '25	Jul '25	Aug '25	Sep '25	Oct '25
Strong Buy	1	1	1	1	1	1
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $10 → $25	Buy	Maintains	$10 → $25	+738.93%	Aug 27, 2025
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $44 → $40	Buy	Maintains	$44 → $40	+1,242.28%	May 16, 2025
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Maintains $16 → $28	Strong Buy	Maintains	$16 → $28	+839.60%	Feb 20, 2025
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $52 → $44	Buy	Reiterates	$52 → $44	+1,376.51%	Nov 15, 2024
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Initiates $16	Strong Buy	Initiates	$16	+436.91%	May 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.16

from -3.11

EPS Next Year

-0.16

from -0.16

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-3.48	-4.81	-9.72	-8.25	-3.11	-0.16	-0.16
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026
High	-0.17	-0.17
Avg	-0.16	-0.16
Low	-0.16	-0.16

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.